br18

Miransertib mesylate is a selective AKT inhibitor that binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K AKT signaling pathway. This may result in reduction in tumor cell proliferation and the induction of tumor cell apoptosis.

NIBR189是 EBI2（GPR183）小分子拮抗剂(IC50:11 nM)。